Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: Summary of a public health/clinical collaborative meeting

Genetics in Medicine

Volumn 14, Issue 1, 2012, Pages 152-162

  Bellcross, Cecelia A ^a,b   Bedrosian, Sara R ^a   Daniels, Elvan ^c   Duquette, Debra ^d   Hampel, Heather ^e   Jasperson, Kory ^f   Joseph, Djenaba A ^g   Kaye, Celia ^h   Lubin, Ira ^g   Meyer, Laurence J ⁱ   Reyes, Michele ^a   Scheuner, Maren T ^j   Schully, Sheri D ^k   Senter, Leigha ^e   Stewart, Sherri L ^g   St Pierre, Jeanette ^a   Westman, Judith ^e   Wise, Paul ^l   Yang, Vincent W ^b   Khoury, Muin J ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ DEPARTMENT OF VETERANS AFFAIRS   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

colorectal cancer; genetic screening; genetic testing; HNPCC; Lynch syndrome

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GENETIC RISK; GENETIC SCREENING; GENOME ANALYSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; POPULATION RESEARCH; PUBLIC HEALTH SERVICE; RELATIVE;

EID: 85027925871     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.0b013e31823375ea     Document Type: Article

References (62)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2007 incidence and mortality web-based report. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute: Atlanta, GA, 2010. http://www.cdc.gov/uscs. Accessed 15 January 2011.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
3. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124:544-560. (Pubitemid 36169269)
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932. (Pubitemid 36298000)
5. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352: 1851-1860.
6. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
7. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
8. AHRQ. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications, 2007. http://www.ahrq.gov/clinic/tp/hnpcctp.htm. Accessed 15 December 2010.
9. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26: 5783-5788.
10. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104.
11. Peres J. To screen or not to screen for Lynch syndrome. J Natl Cancer Inst 2010;102:1382-1384.
12. Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 2010;8:597-601.
13. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456. (Pubitemid 29258894)
14. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268. (Pubitemid 38256271)
15. de la Chapelle A, Palomaki G, Hampel H. Identifying Lynch syndrome. Int J Cancer 2009;125:1492-1493.
16. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7817. (Pubitemid 44289242)
17. Hampel H, Panescu J, Lockman J, et al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res 2007;67:9603. (Pubitemid 47535953)
18. Evaluation of Genomic Applications in Practice and Prevention. http://www. egappreviews.org. Accessed 15 December 2010.
19. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
20. Botkin JR, Teutsch SM, Kaye CI, et al. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med 2010;12:228-235.
21. Healthy People 2020: genomics objectives. http://www.healthypeople. gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=15. Accessed 15 December 2010.
22. Barrow E, Alduaij W, Robinson L, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 2008;74:233-242.
23. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-110. (Pubitemid 27033972)
24. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005;129:415-421. (Pubitemid 41096629)
25. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-1627.
26. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-2310.
27. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75:141-149.
28. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extraendometrial cancer in the Lynch syndrome. Int J Cancer 2008;123: 444-449. (Pubitemid 351842032)
29. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135:419-428.
30. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010;138:2300-2306.
31. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834. (Pubitemid 30243745)
32. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793-4797.
33. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002;45:1588-1594. (Pubitemid 35471007)
34. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006;130:665-671. (Pubitemid 43374516)
35. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-269. (Pubitemid 43113031)
36. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colorectal cancer screening (v1.2010), 2010. http://www.nccn. org/professionals/physician-gls/PDF/colorectal-screening.pdf. Accessed 15 December 2010.
37. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-1517. (Pubitemid 44465515)
38. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44:353-362. (Pubitemid 46953715)
39. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009;10:400-408.
40. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-1487. (Pubitemid 28226275)
41. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121:198-213. (Pubitemid 32591530)
42. Menigatti M, Di Gregorio C, Borghi F, et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer 2001;31:357-361. (Pubitemid 32622712)
43. Capel E, Fléjou JF, Hamelin R. Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene 2007;26:7596-7600. (Pubitemid 350207716)
44. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009;46:793-802.
45. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009;48:737-744.
46. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005;4:255-265. (Pubitemid 41242196)
47. Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 2009;11:126-130.
48. South CD, Yearsley M, Martin E, Arnold M, Frankel W, Hampel H. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med 2009;11:812-817.
49. Hall MJ. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients-will the ends justify the means? J Natl Compr Canc Netw 2010;8: 606-611.
50. Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med 2011;13:356-360.
51. Overbeek LI, Ligtenberg MJ, Willems RW, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008;32:1246-1251.
52. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-2200. (Pubitemid 30350210)
53. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218. (Pubitemid 29144749)
54. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010;102:193-201.
55. Taplin SH, Clauser S, Rodgers AB, Breslau E, Rayson D. Interfaces across the cancer continuum offer opportunities to improve the process of care. J Natl Cancer Inst Monographs 2010;2010:104-110.
56. Taplin SH. Talk presented at Multilevel interventions across the cancer care continuum. Mutilevel interventions in health care: building the foundation for future research. Las Vegas, Nevada, 2011. http://dccps.nci.nih.gov/mli/ background-2011.pdf. Accessed 10 June 2011.
57. Khoury MJ, Bowen MS, Burke W, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 2011;40:486-493.
58. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618. (Pubitemid 46224239)
59. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45:1890-1896.
60. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011;60:950-957.
61. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006;130:1865-1871. (Pubitemid 43668858)
62. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121:195-197.